Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Mohammad Ammad Ud Din, Todd C Knepper, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Lubomir Sokol, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Bijal D. Shah, Javier Pinilla-Ibarz

Blood (2023) 142 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2023-179658

Published: 2023

Journal Articles

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Aditi Saha, Junmin Whiting, Mohammad Ammad-ud-din, Cole Powell, Kristen Flores, Felix Sanjay, Humaira Sarfraz, Khushali Jhaveri, Michael V. Jaglal, Katherine Tobon, Hayder Saeed, Celeste M. Bello, Bijal D. Shah, Leidy Lismeris Isenalumhe, Javier Pinilla-Ibarz, Lubomir Sokol, Julio C Chavez, Ning Dong

Blood (2023) 142 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2023-188211

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

Jeremy S. Abramson, Jon E. Arnason, Ann S. LaCasce, Robert Redd, Jeffrey A. Barnes, Lubomir Sokol, Robin Joyce, David Avigan, Donna Neuberg, Ronald W. Takvorian, Ephraim P. Hochberg, Celeste M. Bello

Blood (2019) 134 (7): 606–613.

https://doi.org/10.1182/blood.2019001272

Published: 2019

Includes: Supplemental data

Journal Articles

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Jeremy S. Abramson, MD MMSc, Robert A. Redd, MS, Jeffrey A. Barnes, MD PhD, Elizabeth Bengtson, MD, Ronald W. Takvorian, MD, Lubomir Sokol, MD PhD, Frederick Lansigan, MD, Philippe Armand, MD PhD, Bijal D. Shah, MD, Eric D Jacobsen, MD, Donna S Neuberg, ScD, Ann S. LaCasce, MD MSc, Celeste M. Bello, MD

Blood (2018) 132 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2018-99-115173

Published: 2018

Journal Articles

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

Ariel Felipe Grajales-Cruz, MD, Julio C. Chavez, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Francisco Perez Leal, MD, Jose Sandoval-Sus, MD, Rami S. Komrokji, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Bijal D. Shah, MD, Lubomir Sokol, MD PhD, Celeste M. Bello, MD, Javier Pinilla Ibarz, MD

Blood (2018) 132 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2018-99-111564

Published: 2018

Journal Articles

Impact of Serum Albumin in the Prognosis of Myc-Positive Aggressive B-Cell Lymphomas: Potential for a Novel Prognostic Score

Chetasi Talati, MD, Andrew Kuykendall, MD, Jori Kaplan, MD, Jose D Sandoval-Sus, MD, Samir Dalia, MD, Bijal D. Shah, MD, Celeste M. Bello, MD, Farhad Khimani, MD, Paul A. Chervenick, MD, Ernesto Ayala, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, Julio C. Chavez, MD

Blood (2016) 128 (22): 1870.

https://doi.org/10.1182/blood.V128.22.1870.1870

Published: 2016

Journal Articles

Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial

Javier Pinilla-Ibarz, Julio C Chavez, MD, Elyce Turba, RN, MSN, OCN, Lisa Nodzon, PhDANP, Jennifer rock-Klotz, BA, Samir Dalia, MD, Rami S. Komrokji, MD, Frederick L. Locke, MD, Mohamed A Kharfan-Dabaja, MD, Celeste M. Bello, MD

Blood (2015) 126 (23): 2941.

https://doi.org/10.1182/blood.V126.23.2941.2941

Published: 2015

Journal Articles

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Jose D Sandoval-Sus, MD, Julio C Chavez, MD, Samir Dalia, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Viet Q. Ho, PharmD, RPh, BCOP, Lisa Nodzon, PhDANP, Mohamed A. Kharfan-Dabaja, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, MD PhD, Javier Pinilla-Ibarz

Blood (2015) 126 (23): 2945.

https://doi.org/10.1182/blood.V126.23.2945.2945

Published: 2015

Journal Articles

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Eric D. Jacobsen, Jeff P. Sharman, Yasuhiro Oki, Ranjana H. Advani, Jane N. Winter, Celeste M. Bello, Gary Spitzer, Maria Corinna Palanca-Wessels, Dana A. Kennedy, Pamela Levine, Jing Yang, Nancy L. Bartlett

Blood (2015) 125 (9): 1394–1402.

https://doi.org/10.1182/blood-2014-09-598763

Published: 2015

Includes: Supplemental data

Journal Articles

Multivariate Survival Analysis of Transformed Lymphoma in the Chemoimmunotherapy Era: Impact of the NCCN International Prognostic Index

Patrick T. Griffin, MD, Samir Dalia, MD, Bijal D. Shah, MD, Lubomir Sokol, MD PhD, Celeste M. Bello, MD, Paul A. Chervenick, MD, Eduardo M. Sotomayor, MD, Julio C Chavez, MD

Blood (2014) 124 (21): 2981.

https://doi.org/10.1182/blood.V124.21.2981.2981

Published: 2014

Journal Articles

Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis

Patrick T. Griffin, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Lubomir Sokol, MD PhD, Paul A. Chervenick, MD, Ernesto Ayala, MD, Jianguo Tao, MD PhD, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2014) 124 (21): 4424.

https://doi.org/10.1182/blood.V124.21.4424.4424

Published: 2014

Journal Articles

A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma

Bryan J Little, MPH, Julio C Chavez, MD, Celeste M. Bello, MD, Paul Chervenick, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2013) 122 (21): 1702.

https://doi.org/10.1182/blood.V122.21.1702.1702

Published: 2013

Journal Articles

Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia

Samir Dalia, MD, Jason B. Brayer, MD, PhD, Julio C Chavez, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Pedro Horna, M.D., Hailing Zhang, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2013) 122 (21): 5290.

https://doi.org/10.1182/blood.V122.21.5290.5290

Published: 2013

Journal Articles

A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)

Samir Dalia, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Paul A. Chervenick, MD, Bryan J Little, MPH, Najla H Al Ali, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Ji-Hyun Lee, PhD, Kate Fisher, MA, Zachary Thompson, PhD, Bong-jin Choi, MA, Bijal D. Shah, MD

Blood (2013) 122 (21): 4267.

https://doi.org/10.1182/blood.V122.21.4267.4267

Published: 2013

Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Blood (2013) 122 (21): 1632.

https://doi.org/10.1182/blood.V122.21.1632.1632

Published: 2013

Journal Articles

Locally Directed Therapy In Limited Stage Mantle Cell Lymphoma

Samir Dalia, MD, Julio C Chavez, MD, Celeste M. Bello, MD, Paul A. Chervenick, MD, Lubomir Sokol, MD, Ph.D, Jianguo Tao, MD, PhD, Eduardo M. Sotomayor, MD, Bijal D. Shah, MD

Blood (2013) 122 (21): 5057.

https://doi.org/10.1182/blood.V122.21.5057.5057

Published: 2013

Journal Articles

What Is The Optimal Dose Of Methotrexate In Primary Central Nervous System Lymphoma Treatment Regimens?

Samir Dalia, MD, Samantha L Price, PharmD, Peter Forsyth, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Michael V. Jaglal, MD

Blood (2013) 122 (21): 3040.

https://doi.org/10.1182/blood.V122.21.3040.3040

Published: 2013

Journal Articles

Extranodal Diffuse Large B Cell Lymphoma In The Rituximab Era and The Risk of Central Nervous System (CNS) Relapse. A Single Center Experience From 2008-2012

Christina Tsao, MD, Kate Fisher, MA, Ji-Hyun Lee, PhD, Julio C Chavez, MD, Samir Dalia, MD, Celeste M. Bello, MD

Blood (2013) 122 (21): 4330.

https://doi.org/10.1182/blood.V122.21.4330.4330

Published: 2013

Journal Articles

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

Andres Forero-Torres, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J. Kipps, MD, PhD, Fritz Offner, MD, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, MD, Jaime Pérez de Oteyza, Jose Francisco Tomas, MD, Antonio Cuneo, MD, Nairouz Elgeioushi, MPH, Trishna Goswami, MD, Ramy Ibrahim, MD, Ronald Herbst, PhD, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 1810.

https://doi.org/10.1182/blood.V122.21.1810.1810

Published: 2013

NARROW

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma

A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia

Impact of Serum Albumin in the Prognosis of Myc-Positive Aggressive B-Cell Lymphomas: Potential for a Novel Prognostic Score

Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression

Multivariate Survival Analysis of Transformed Lymphoma in the Chemoimmunotherapy Era: Impact of the NCCN International Prognostic Index

Increased Treatment Intensity Is Not Associated with a Survival Benefit in Patients with Low and Intermediate Risk Mantle Cell Lymphoma, a Retrospective Analysis

A Retrospective Evaluation Of Insurance Status As It Relates To Outcomes In Diffuse Large B-Cell Lymphoma

Concurrent Epstein Barr Virus Viremia and Hodgkin Lymphoma In Two Patients With Chronic Lymphocytic Leukemia

A New Prognostic Index In Diffuse Large B-Cell Lymphoma Using Serum Albumin: A Pilot Study Evaluating The Albumin Adjusted-International Prognostic Index (A-IPI)

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Locally Directed Therapy In Limited Stage Mantle Cell Lymphoma

What Is The Optimal Dose Of Methotrexate In Primary Central Nervous System Lymphoma Treatment Regimens?

Extranodal Diffuse Large B Cell Lymphoma In The Rituximab Era and The Risk of Central Nervous System (CNS) Relapse. A Single Center Experience From 2008-2012

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only